MW-C1
/ Mabwell (Shanghai) Biosci
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 26, 2025
MW-C1, a novel CLDN1-targeting ADC demonstrates compelling anti-tumor efficacy and favorable safety profile in preclinical studies
(AACR 2025)
- "MW-C1 demonstrated potent anti-tumor efficacy and a favorable safety profile, highlighting its potential as a transformative therapeutic candidate for the treatment of CLDN1-overexpressing malignancies."
Preclinical • Cervical Cancer • Head and Neck Cancer • Hepatocellular Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • CLDN1
1 to 1
Of
1
Go to page
1